DHT blockers can cause erectile dysfunction, but the risk is lower than most people expect. In clinical trials of finasteride, the most commonly used DHT blocker for hair loss, about 1.3 to 1.4% of men experienced ED, compared to 0.7 to 0.9% on a placebo. That means the actual drug-related risk is roughly one extra case for every 100 to 150 men taking it.
How DHT Blockers Affect Sexual Function
DHT (dihydrotestosterone) is a potent form of testosterone responsible for male pattern hair loss and prostate growth. DHT blockers, known as 5-alpha reductase inhibitors, work by reducing how much of this hormone your body produces. The problem is that DHT also plays a role in sexual function, including maintaining erections, libido, and ejaculatory volume.
When you lower DHT levels systemically, some men notice changes across all three areas. In studies of over 1,500 men taking the hair loss dose, sexual side effects of any kind occurred in about 3.8 to 4.2% of users versus roughly 2.1 to 2.2% on placebo. Those side effects included decreased sex drive, reduced ejaculate volume, and erectile dysfunction. So while ED gets the most attention, it’s actually one piece of a broader set of possible sexual changes.
Finasteride vs. Dutasteride
Dutasteride blocks more DHT than finasteride does, which raises a logical question: does it cause more sexual problems? A head-to-head trial of 1,630 men with enlarged prostates found that the answer is essentially no. Impotence occurred in 7% of dutasteride users versus 8% of finasteride users, and decreased libido was reported in 5% versus 6%. These rates are higher than in hair loss trials because the prostate doses are larger and the patient population is older, but the two drugs performed almost identically in terms of sexual side effects.
The takeaway is that even though dutasteride suppresses DHT more aggressively, it doesn’t appear to carry a meaningfully higher risk of ED than finasteride.
The Hair Loss Dose vs. the Prostate Dose
Finasteride is prescribed at 1 mg daily for hair loss and 5 mg daily for enlarged prostate. The higher dose used in prostate studies shows impotence rates around 6 to 8%, while the 1 mg hair loss dose shows rates closer to 1.3 to 1.4%. Part of that gap reflects the higher dose itself, and part reflects the older age of men being treated for prostate issues. Either way, if you’re taking a DHT blocker for hair loss, the absolute risk of ED from the drug is small.
Topical Formulations Lower the Risk Further
Topical finasteride spray has emerged as an alternative that delivers the drug directly to the scalp while keeping blood levels extremely low. In a phase III trial, peak blood concentrations of finasteride were more than 100 times lower with the topical version compared to the oral pill. Serum DHT dropped by about 34.5% with topical application versus 55.6% with the oral form.
The clinical difference showed up in side effect rates. Sexual adverse events occurred in 2.8% of topical users, 4.8% of oral users, and 3.3% of those on placebo. Zero patients in the topical group discontinued treatment due to sexual side effects, compared to 2.4% in the oral group. For men particularly concerned about ED risk, topical finasteride offers a way to treat hair loss with less systemic DHT suppression.
How Much of the Risk Is Psychological
One of the most debated aspects of DHT blocker side effects is how much of the problem is driven by expectation rather than pharmacology. Researchers have consistently noticed that sexual side effect rates are higher in everyday clinical practice than in controlled trials, and a key study investigated whether a nocebo effect (the opposite of placebo, where expecting a side effect makes it more likely to happen) could explain the gap.
In one study, men who were told about possible sexual side effects before starting finasteride reported significantly higher rates of those effects than men who weren’t given that warning. When the drug was discontinued in informed patients, their side effects resolved within five days, suggesting a strong psychological component. This doesn’t mean the pharmacological risk is zero. The controlled trial data clearly show a real, if modest, difference between drug and placebo groups. But it does mean that anxiety about sexual side effects can amplify or even create the experience of them.
Do Side Effects Go Away After Stopping?
For the majority of men, yes. Clinical trial data consistently show that sexual side effects resolve either during continued treatment or shortly after stopping the medication. In many cases, men who developed side effects early in therapy found they faded even without discontinuing the drug. One study found that side effects “disappeared not only in all men who stopped the drug because of the side effects but also in most of those who continued therapy.”
However, a small number of men report sexual symptoms that persist well beyond discontinuation, a pattern sometimes called post-finasteride syndrome. A retrospective study of 71 men with persistent symptoms found that the average duration of ongoing sexual dysfunction was 40 months after stopping the drug, and when these men were re-interviewed 14 months later, 89% still reported problems. A separate study of 79 men with lasting effects found symptoms persisting for nearly four years after stopping treatment.
These studies specifically selected men who already had persistent problems, so they don’t tell you how common the issue is overall. A larger retrospective cohort of 4,284 men aged 16 to 42 who used low-dose finasteride found a rate of 0.8% for persistent sexual symptoms after discontinuation. Among the 103 men in that group who experienced sexual symptoms during treatment, about a third reported they continued after stopping. The strongest predictor of persistent symptoms was using the drug for longer than seven months.
Putting the Risk in Perspective
The clinical evidence paints a consistent picture. DHT blockers do cause erectile dysfunction in some men, but the absolute risk at hair loss doses is small, roughly 0.5 to 0.7 percentage points above placebo. The vast majority of men who experience sexual side effects recover either on continued treatment or after stopping. A small subset, likely under 1%, develops persistent symptoms that can last months to years. Topical formulations appear to reduce the risk further by limiting how much of the drug enters the bloodstream. And psychological factors, particularly worry about side effects, can meaningfully inflate the likelihood of experiencing them.